Drug Interaction Report
2 potential interactions and/or warnings found for the following 2 drugs:
- inebilizumab
- Velsipity (etrasimod)
Interactions between your drugs
inebilizumab etrasimod
Applies to: inebilizumab, Velsipity (etrasimod)
Using etrasimod together with inebilizumab may increase the risk of serious and potentially life-threatening infections. Because etrasimod effects can continue for up to 5 weeks after the last dose, interactions with other drugs may occur for some time even after you have stopped taking it. Talk to your doctor if you have any questions or concerns. Contact your doctor immediately if you develop signs and symptoms of infection such as fever, chills, diarrhea, sore throat, muscle aches, shortness of breath, blood in phlegm, weight loss, red or inflamed skin, body sores, and pain or burning during urination during or after treatment with these drugs. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Drug and food interactions
etrasimod food
Applies to: Velsipity (etrasimod)
Grapefruit juice may increase the blood levels of etrasimod. You should avoid grapefruit, grapefruit juice, or any supplements that contain grapefruit extract during treatment with etrasimod unless directed otherwise by your doctor. Talk to your doctor if you have any questions or concerns. Contact your doctor if your condition changes or you experience increased side effects, such as fever, high temperature or flu-like symptoms, severe headache, confusion, seizures, dizziness, tiredness, lightheadedness, chest pain, shortness of breath, or irregular or abnormal heartbeat, blurriness or shadows in the center of your vision, and nausea, vomiting, abdominal pain, anorexia, or jaundice and/or dark urine. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
See also:
Uplizna
Uplizna is used to treat adults with neuromyelitis optica spectrum disorder (NMOSD) or ...
Enspryng
Enspryng is used to treat neuromyelitis optica spectrum disorder (NMOSD) in adults who are ...
Deltasone
Deltasone is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Ultomiris
Ultomiris (ravulizumab-cwvz) is used for the treatment of myasthenia gravis, paroxysmal nocturnal ...
Rayos
Rayos (prednisone, delayed-release) is used to treat rheumatoid arthritis, polymyalgia rheumatica ...
Soliris
Soliris infusion is used to treat paroxysmal nocturnal hemoglobinuria (PNH) or neuromyelitis optica ...
Sterapred
Sterapred is used for acute lymphocytic leukemia, adrenocortical insufficiency, allergic reactions ...
Bkemv
Bkemv (eculizumab-aeeb) is an interchangeable biosimilar to Soliris which may be used to treat ...
Epysqli
Epysqli (eculizumab-aagh), a biosimilar to Soliris, targets the complement system to treat ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.